Effective January 1, 2025, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will update its Reslizumab (Cinqair®) utilization criteria to require use of the provider-administered formulations of Fasenra® and Nucala® prior to utilizing Cinqair for all requests. Any existing authorizations for Cinqair will be active through the original prior authorization approval date.
This change applies to all commercial and Administrative Services Only (ASO) members. This policy does not apply to FEP (Federal Employee Program) or Medicare members.
Actions Required Due to These Changes
Providers with members on Cinqair should utilize Fasenra and Nucala before using Cinqair. Any members who are currently using non-preferred Cinqair should be moved to Fasenra or Nucala once their existing authorization ends.
Please continue to submit all requests through Blue e for fastest processing times.
Learn more about Interleukin-5 Antagonists (PDF).
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.